184 results on '"Necela, Brian M."'
Search Results
2. Higher and Sustained Cell-Mediated Immune Responses After 3 Doses of mRNA COVID-19 Vaccine in Patients With Inflammatory Bowel Disease on Anti–Tumor Necrosis Factor Therapy
3. TRPC6 N338S is a gain-of-function mutant identified in patient with doxorubicin-induced cardiotoxicity
4. BRAFV600E/pTERT double mutated papillary thyroid cancers exhibit immune gene suppression.
5. Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade
6. Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients
7. Data from Detection of Redundant Fusion Transcripts as Biomarkers or Disease-Specific Therapeutic Targets in Breast Cancer
8. Supplementary Table 1 from Detection of Redundant Fusion Transcripts as Biomarkers or Disease-Specific Therapeutic Targets in Breast Cancer
9. Supplementary Figure 1 from Detection of Redundant Fusion Transcripts as Biomarkers or Disease-Specific Therapeutic Targets in Breast Cancer
10. Supplementary Table 4 from Detection of Redundant Fusion Transcripts as Biomarkers or Disease-Specific Therapeutic Targets in Breast Cancer
11. Supplementary Table 3 from Detection of Redundant Fusion Transcripts as Biomarkers or Disease-Specific Therapeutic Targets in Breast Cancer
12. Supplementary Table 2 from Detection of Redundant Fusion Transcripts as Biomarkers or Disease-Specific Therapeutic Targets in Breast Cancer
13. The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes
14. Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination.
15. Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer
16. Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination
17. Regulation of Glucocorticoid Receptor Function During the Cell Cycle
18. Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial
19. Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial
20. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer
21. Trpc6 Promotes Doxorubicin-Induced Cardiomyopathy in Male Mice With Pleiotropic Differences Between Males and Females
22. MEN1 Mutations in Hürthle Cell (Oncocytic) Thyroid Carcinoma
23. Peroxisome Proliferator-activated Receptor γ Down-regulates Follistatin in Intestinal Epithelial Cells through SP1
24. Clinical and Molecular Features of Hürthle Cell Carcinoma of the Thyroid
25. RNA Sequencing Identifies Multiple Fusion Transcripts, Differentially Expressed Genes, and Reduced Expression of Immune Function Genes in BRAF (V600E) Mutant vs BRAF Wild-Type Papillary Thyroid Carcinoma
26. Functional Genomic Analysis Reveals Cross-talk between Peroxisome Proliferator-activated Receptor γ and Calcium Signaling in Human Colorectal Cancer Cells
27. Peroxisome Proliferator-activated Receptor γ Promotes Epithelial to Mesenchymal Transformation by Rho GTPase-dependent Activation of ERK1/2
28. Crystallization of the human glucocorticoid receptor ligand binding domain: a step towards selective glucocorticoids
29. RS5444, a novel PPARγ agonist, regulates aspects of the differentiated phenotype in nontransformed intestinal epithelial cells
30. A novel bioinformatics pipeline for identification and characterization of fusion transcripts in breast cancer and normal cell lines
31. Association of Genetic Variants at TRPC6 With Chemotherapy-Related Heart Failure
32. Toll-like receptor 4 mediates cross-talk between peroxisome proliferator-activated receptor γ and nuclear factor-κB in macrophages
33. A Single Amino Acid Change in the First Zinc Finger of the DNA Binding Domain of the Glucocorticoid Receptor Regulates Differential Promoter Selectivity
34. Mechanisms of Glucocorticoid Receptor Action in Noninflammatory and Inflammatory Cells
35. Development of a flow cytometric assay to study glucocorticoid receptor-mediated gene activation in living cells
36. Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2+ breast cancer samples
37. Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial
38. Comprehensive Genomic Profiling of a Rare Thyroid Follicular Dendritic Cell Sarcoma
39. Abstract 3377: Simultaneous analysis of the mutational landscape and RNA and protein expression profile of HER2-positive breast cancer using 3D BiologyTM
40. Correction: Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth
41. Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial
42. Correction: Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth
43. Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth
44. Assessment of Tumor Heterogeneity, as Evidenced by Gene Expression Profiles, Pathway Activation, and Gene Copy Number, in Patients with Multifocal Invasive Lobular Breast Tumors
45. Abstract P6-07-03: An exhaustive algorithm for detecting copy number aberrations and large structural variants in whole-genome mate-pair sequencing data
46. Correction: Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors
47. Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors
48. Pathophysiological Roles of PPARγ in Gastrointestinal Epithelial Cells
49. An exhaustive algorithm for detecting copy number aberrations and large structural variants in whole-genome, mate-pair sequencing data.
50. Identification and targeting of M-phase progression downstream of HER2 in trastuzumab-sensitive and -resistant breast cancer cell lines.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.